India Symposium 2010 Pharmaceuticals

8/2/2019 India Symposium 2010 Pharmaceuticals

1/16

IndIa SympoSIum InduStry report

Pharmaceuticals

www. ind ia -sympos ium .org

zurich 2010


2/16

www. ind ia-s ymp os ium .o rg

con:

d. Sig migsil

ind sypo

e-: [email protected]

con:

us devv


Knowdg Pn

con:

Shi HidWok


Dgn Pn


3/16

3Pharmaceuticals

ContentS

exv sy 5

indy Ovvw 6

Gow Dv 9

mjo Py 10

mjo rgon nd Po 11

tnd nd Oppon 12

l o abbvon 13appndx 14

D 15

Ii Ssi Is rPharmaceuticals


4/16


5/16

5Pharmaceuticals

t indn p ndy now wod

d g (10% o gob ) n o

vo o p pod podd nd

nkd 14 n o vn gnd. t

ndy dp poon pd ind bd

ong bnd n n p p.

t ndy gy gnd w ond 24000

py (bo 330 n ognzd o) poyng

o o 3 on pop. t op 10 p

opn on o 35% o o p

. t d o k d v

ong dbon nwok nd fd o, nd

onnoy nvovd n pod n.

t p o gng joonbo o indn xpo w xpo nng

ng o nggb on n 1990 o v o

usD 7.64 bon n FY*-08, nd ood usD 8.27

bon n FY-09. us nd eop p xpo

dnon, oowd by cn nd en eop,

a nd ln a (FY-08). t xpo o

dg, p & fn o ind

v gown opond nn gow

(caGr) o 21.1% (n usD ) dng podFY-03 o FY-09. Fogn d nvn n indn

dg nd p gn w ppoxy usD 1.43

bon o ap 2000 o Db 2008.

P opn n ind now pod

bk dg o v p ngdn (aPi)

bongng o jo p gop. con

nng nd (crams) xpd o

gn pd n ndy n ong y. ao on nng, bo gob nnovo

nd p gn jo fndng pofb

o oo podon.

indn p ndy ovng p

v n. i w pvoy vwd p v

ngnng ndy w od on do

k. t now ngng ndy ongon & dvopn, nng gob pn

og xpo, povdng wd ng o v ddd

qy pod nd v, nnovon, pod

y ngn nd ngng k .

howv, do k onn o b p-

nv dp ono gow nd opn

bdng pod kpng ky n nd.

m&a vy o bn on n n n o w n nbond d D-

rnbxy, snof avn sn Bo, abbo

Wokd (non) nd myn mx. sn

g v o gnon xng n k,

nd w gng owd onodon nd

o qon o do opn by m-

Non copn (mNc).

1. exeCutIve Summary

*The period referred to here is April to March


6/16

n Do mk (iNr bon) n to mk z (iNr bon)

Fig 2: Gh Ii ph Is (I Inr Billi)

so: indBn rpo

0 1000800600400200

2003

2004

2005

2006

2007

2008

2009

325.75473.32

341.28520.29

399.89625.66

453.67684.42

554.54893.35

509.46786.1

303.65423.26

Sgs

Bk dg nd oon god

n odn w ppon p

gn p d o n. Gynoogy

g gn ong p pod.

t n-nv pod gn bn ong

k onny; k dd

o 24% n FY-02 o 18% n FY-07 nd

xpd o d o 17% n FY-12.

t jo pod go nd pn n

png k (ov y) dpyd

n Fg 3. in FY-02, n-nv, gonn

dg nd vn/n od o 50% o

do k. By FY-12, y xpd o

on o j 36% o k p .

On o nd, dg o do-v pob,

dod o n nvo y nd oon d w on o 64% o o , p

o 50% n FY-02.

2. InduStry overvIew

Ii phcicl Is

ind now on o gowng p

k n wod. i bn b o xpnd

vn dp gob fnn . t

ndy gown o ony usD 0.32 bon nov

n 1980 o ppoxy usD 21.26 bon n

y 2009-10. t ndy now wod dg n o vo o p

pod podd nd nkd 14 n o

vn gnd. rob do dnd, gowng

pn o gn nd vob ogn

xng pd o gow.

t indn p k gnd o

vn o usD 19.22 bon n FY-09.

Fg 1 & Fg 2 ow gow nd n indn

P ndy o FY-03 o FY-09 n usD

nd iNr pvy.

Fig 1: Gh Ii ph Is (I uSd billi)

0.00 25.0020.0015.0010.005.00

n Do mk (iNr bon) n to mk z (iNr bon)

2003

2004

2005

2006

2007

2008

2009

8.656.21

7.08

11.587.59

9.03

10.03

12.65

11.9319.22

19.52

15.13

14.13

10.28

so: indBn rpo


7/16

7Pharmaceuticals

Fig 3: p h Ii dsic Fli

mk (pcg bk-)

n Pn/ang, Gynoog & Doogy n an-nvn Vn/mn n Gonnn rpoy n cdovn No/cNs n andbnn O

so: ims h inoon nd conng sv ind Pv. ld (OrGims),crisil, rvw o Foon mk, ind (2008)

0 10080604020

2003

2004

2005

24 14 12 10 8 5 3 15

21 17 8 11 9 10 6 5 13

20 18 9 11 9 10 5 4 13

9

Gdp-Sh

Fig 4: Gdp Sh

n GDP n Png s

0 12501000750500250

2006

2007

2008

2009

967.1

789.9

736.3

906.6 2.1%

2.0%

1.9%

1.9%

so: indBn rpo

es: Gics apI L h w

ind xpo dg nd, v p

ngdn (aPi), fnd dog oon (FDF),

bop nd n v. t ndyFY-09 xpo vn w d bo usD

8.27 bon, gn dg nd aPi xpd o

b oponn dvng xpo. Fg

5 & Fg 6 ow gow nd n xpo nd

po o FY-03 o FY-09 n usD nd iNr

pvy.

Fig 5: t i es Is, Ii(Fy-03 Fy-09, uSd Billis )

n expo (usD bon) n ipo (usD bon)

so: indBn rpo

0.00 4.002.00 6.00 8.00 10.00

2003

2004

2005

2006

2007

2008

2009

2.620.59

0.643.31

0.703.97

1.025.02

1.305.51

1.67

1.84

7.64

8.27


8/16

tbl 1: m iig Cis Ii

(s miis Cc, Ii)

rk Iig C pcg sh i Iisphcicl es

1 usa 18.48%

2 r 3.95%

3 Gny 3.75%4 a 3.69%

5 uK 3.21%

6 so a 2.93%

7 cnd 2.84%

8 Bz 2.65%

9 Ng 2.61%

10 ukn 1.79%

Fig 6: t i es Is, Ii

(Fy-03 Fy-09, Inr Billi)

n expo (iNr bon) n ipo (iNr bon)

so: indBn rpo

0 16080 240 320 400

2003

2004

2005

2006

2007

2008

2009

128.2628.65

29.56152.13

31.39178.57

45.15222.16

58.67 249.42

67.34

85.52

307.6

384.33

tb 1 ow ony-w bk-p o xpo

o FY-08. a p d jo xpo b

us nd eop. t P expo Pooon

con ( p by govnn p

ondon o Nn Fv Y ann Pn) gon--bp f

(rcmc), w ndoy o po nd xpo

o ood. i o poo p

pod og v o ogn k, wokop

nd xbon. Px o od by/

nd nn db o p

xpo nd pob n xpong p

pod.


9/16

9Pharmaceuticals

3. GrowtH drIverS

micl Isc G pnon o d nn w dv onpon o d nd pod.G pnon o d nn xpd b o Entry of foreign players Increase in the size and disposable income of Indian household

Css ind povd o n, nn, ngn ponn ow o w vb n dvopd ono, w d o ow ov o.typy, n on o ov 40% o o dg dvopn o;

d o o ng yp dg n ind 60% o n us.

G plicis Po x ody o nd opon n pfd sp eono Zono nddvopd , x xpon o pof nd o xpo, b dponown nd ddon o p r&D xpnd nng ndyvn.

mig h vl Chi

invn n r&D pb nd n v gon p n bo nd ndgovnn o.

ps t nn o td rd in Popy rg (triPs) n 2005 d o n

n n onfdn v o p opn n indn k. sn2005, 15 pnd pod v bn oy nodd n indn k.indn p opn v fd nb o non-nngng po ndoon pn.

mgs acqisiis lg indn p opn nng pn n gdk goby, w nd d-zd opn ong on -gd k ln a.

e pil ind p opn v d o o us o o k,ndng eop nd Jpn. indn opn v nvd o n usD 1.2 bon neopn k.


10/16

4. major pLayerS

C rbLbis L.

d. rsLbis

Cil nichls pil( pilHlhc)

tphcicls

dscii rnbxy ong op 100pn wod nd

15 gowng opny.

t opny ggvypng nnonongy. i o gnd kdp nind, vgng ong bndbdng k.

D. rddy vyngd, gobp

opny wpovn pb ndpn o pv n.t opnynaPi nd fnddog o.

cp 31wod-nng pd

o ony,w dddpn oonoogy pod,oon, ndn, ongo. cppod on o wd ngo pod nddog o.

No Pd xn w 1988 qon

o Nolboo ndgw og o g,qonnd n.t opnyop n o onng.

t opny py nvovdn no dov,

cn Nvosy (cNs)py, n-db,gynoogy,doogy ndgonnpod.

rs uSd 1.67 bon(FY-09)

1.56 bon(FY-10)

1.19 bon(FY-10)

570 on(FY-10)

407 on(FY-10)

pfbili uSd 61.2 on(FY-09)

78.29 on(FY-10)

241.4 on(FY-10)

93 on(FY-10)

51 on(FY-10)

tbl 2: m 5 pls dsic

tbl 3: m 5 pls Fig (Ii ois)

C GlSihKli* Sf ais* pfz* nis* asZc*

dscii i on o bgg

popn n wod, w nd 7% n gobpk.

snof-avn non

popny, w o-gppon goby.

Pfz ono od

popn n wod. i bn n oponn 1849 nd d o v g n wod.

Nov wd n 1996

og go cb-Ggy ndsndoz. i opn 140 onnd opoy ngo ppoxy100,000.

i gob,ngd

bopopny nd poond n op 6% n Dow JonWod nd stOXXsnbyindx o po.

rs uSd 410 on(FY-09)

Na 170.8 on(FY-09)

138 on(FY-10)

85.21 on(FY-09)

pfbiliuSd 107.5 on(FY-09) Na 29.43 on(FY-09) 26 on(FY-10) 12.38 on(FY-09)


11/16

11Pharmaceuticals

5. major reGuLatIonS and poLICIeS

rgl Fk t n goy body n ind cn Dg sndd cono Ognon(cDscO), w op nd mny o h nd Fy W. t Dgcono Gn o ind (DcGi), wo ppov n o dg bo nnd v, pd ov cDscO.

FdI rgli in p opn, 100% FDi pd og o o.howv, o nb dg nd p nd og obnn DNa noogy nd / gd oon, po govnnppov qd. Fo bk dg, no nd nng qd. Fogn

nvn po 51% pd n o bk dg, nd ndoon. Fo ov 51% k, no kn p on -o- b,py n podon o dg o b g/ ng nw noogy.

dg ic cl (dpCo) Ky ng n ndy dg p ono od (DPcO).t o gon on bk dg, on oon nd on ov pofby. t d n o o pb o pogv o png oy. tnw P Poy 2006, w popo o bng 354 n dg ndp ono no bn ofy pd y nd bn ongy oppod by p ndy.

mcig Cda mnng n nd o oow good nng p (GmP) d n sd m o Dg nd co a nd nd o ono o WhO nd

nnon ndd o podon. ind oow d dg goy y wponb dvdd bwn n nd o. t cn Dg aoy(cDa), p n 2007, xpd o pov nonng o non dggo, no noy o nng nd povn n dg gon.


12/16

6. trendS and opportunItIeS

Lshi psii Glbl psc

t popy o indn P ndy nd gnfny b o gob pn nd dp poon n aiDs dn k. a , nb o indn opn v bo p o n gn w jo aiDs dgbd on lvdn, svdn, Zdovdn, Nvpn o b ppd o anon.

Sgic pshis h ris

t bn n g pnp o indn p opn wov py:

1. GVK Bon pnd w Wy

2. Jbn pnd w Fo lboo, agn nd e ly3. Zyd cd pnd w Ko Bo aB & Poong P

Cs ag D o o dvng n on nng nd , mNc ngowd on ind w o gnfn o bnf. ind o o dvng o opv dg p.

n dls lnng d w mNc o nw n nd dg dvy y onw oppon. D qon o P h by abbo lb nd byo o joy n rnbxy by Jpn dg jo D snkyo n owdonodon o py n o.

r&d Growth opportunities for R&D exist in the biotechnology generics (biosimilars) andbop o. W pod pn g, nnovon & wpy ky o n dvopng nw pod.

In the area of clinical evaluation at the time of multi-centre trials, India provides a strongb d o vby o n n dv p .P opn vgng on v o crO o .

n as Contract R&D services such as custom synthesis, clinical trials, clinical datangn, boqvn ng, by ng o nw o o on.

Entry of private players in the insurance sector has given a boost to the pharmaopn d o nng p p xpnd on .

Managed health-care/pharmaceutical benet management is also expected to have abg p on indn p k.

Shiig Fcs h uS

indn opn xpndng ozon byond us o k eopn k nd Jpn (wod ond-g p k us).t d o nng png p, nkng gn nd nng gon n us. indn opn v dy nvd bo usD 1.2 bon n eopn k.


13/16

13Pharmaceuticals

7. LISt oF aBBrevIatIonS

AIDS Acquired Immune Deciency Syndrome

API Active Pharmaceuticals and Initiatives

ASSOCHAM Associated Chambers of Commerce and Industry of India

CAGR Compound Annual Growth Rate

CDA Central Drug Authority

CDSCO Central Drug Standard Control Organisation

CNS Central Nervous System CRAMS Contract Manufacturing and Research

CRISIL Credit Rating Information Services of India Limited

CRO Contract Research Organization

CVS Cardio Vascular System

DCGI Drug Controller General of India

DNA Deoxyribonucleic Acid

DPCO Drug Price Control Order

FDA Food and Drug Administration

FDFs Finished Dosage Formulations FDI Foreign Direct Investment

FY Financial Year

GDP Gross Domestic Product

GMP Good Manufacturing Practices

HIV - Human Immunodeciency Virus

IMS - Intercontinental Medical Statistics

INR - Indian National Rupee

MNC MultiNational Companies

M&A - Mergers and Acquisitions OTC Over the Counter

PPP Public Private Partnership

RCMC - Registration cum Membership Certicate

R&D - Research and Development

TRIPS Trade Related Intellectual Property Rights

US United States

USD United States Dollar

WHO World Health Organization


14/16

8. appendIx

Scs:

Is i

Indian Business

Ministry of Pharmaceuticals

Indian Pharmaceutical Association

Indian Pharmaceutical Industry Segments

m plicis rglis:

Central Drug Standard Control Organization

Indian Pharmaceutical Association

Pharmaceutical Drug Manufacturers

Federation of Indian Chambers of Commerce and Industry

m pls:

Dr. Reddy Piramal Healthcare

Cipla

Biocon

Ranbaxy

Equity Master (Glaxo Smith Kline)

Equity Master (Pzer)

Equity master (Novartis)

Sano Aventis

Astra Zeneca

Gh dis:

Pharmabiz

Biospectrum India

Pharmaceutical Drug Manufacturers

Economic Times

ts iis:

Pharmaceutical Industry Indian Business Overview

Analyst Report


15/16

15Pharmaceuticals

9. dISCLaImer

t noon onnd n bn obnd o o bvd o b b. ind sypo &

evv d wn o y, opn o dqy o noon. ind

sypo & evv v no by o o, oon o ndq n noon onnd

n o o npon o.


16/16

www. ind ia -sympos ium . org

son 98306 Z, swznd

Pon +41 43 2559188

Fx +41 43 2559188

Documents

India Symposium 2010 Pharmaceuticals